PuraPharm Corporation Limited
HKEX:1498.HK
0.69 (HKD) • At close September 17, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2024 Q2 | 2023 Q4 | 2023 Q2 | 2022 Q4 | 2022 Q2 | 2021 Q4 | 2021 Q2 | 2020 Q4 | 2020 Q2 | 2019 Q4 | 2019 Q2 | 2018 Q4 | 2018 Q2 | 2017 Q4 | 2017 Q2 | 2016 Q4 | 2016 Q2 | 2015 Q4 | 2015 Q2 | 2014 Q4 | 2014 Q2 | 2013 Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 207.627 | 211.778 | 195.081 | 217.309 | 230.76 | 356.835 | 302.757 | 321.383 | 280.432 | 362.321 | 333.558 | 358.899 | 386.604 | 328.473 | 263.093 | 323.737 | 212.249 | 286.998 | 186.902 | 210.746 | 155.606 | 91.588 |
| Cost of Revenue
| 96.075 | 107.671 | 84.342 | 105.926 | 81.557 | 130.579 | 107.162 | 116.899 | 116.227 | 157.176 | 141.113 | 140.31 | 150.293 | 113.483 | 82.225 | 116.541 | 70.641 | 100.266 | 67.902 | 77.076 | 57.165 | 33.56 |
| Gross Profit
| 111.552 | 104.107 | 110.739 | 111.383 | 149.203 | 226.256 | 195.595 | 204.484 | 164.205 | 205.145 | 192.445 | 218.589 | 236.311 | 214.99 | 180.868 | 207.196 | 141.608 | 186.732 | 119 | 133.67 | 98.441 | 58.028 |
| Gross Profit Ratio
| 0.537 | 0.492 | 0.568 | 0.513 | 0.647 | 0.634 | 0.646 | 0.636 | 0.586 | 0.566 | 0.577 | 0.609 | 0.611 | 0.655 | 0.687 | 0.64 | 0.667 | 0.651 | 0.637 | 0.634 | 0.633 | 0.634 |
| Reseach & Development Expenses
| 3.887 | 6.548 | 8.439 | 12.142 | 8.063 | 12.833 | 11.117 | 13.363 | 7.415 | 22.629 | 10.855 | 17.352 | 9.015 | 10.201 | 9.083 | 9.902 | 8.213 | 8.514 | 7.089 | 8.817 | 7.316 | 0 |
| General & Administrative Expenses
| 0 | 90.5 | 80.607 | 77.71 | 80.006 | 85.857 | 82.286 | 77.289 | 75.677 | 118.913 | 105.707 | 75.393 | 99.212 | 87.414 | 85.79 | 64.578 | 66.271 | 44.178 | 61.919 | 35.69 | 37.072 | 20.257 |
| Selling & Marketing Expenses
| 0 | 41.485 | 50.173 | 75.025 | 82.358 | 127.562 | 92.444 | 113.761 | 96.778 | 110.356 | 115.856 | 114.016 | 115.979 | 111.147 | 80.606 | 88.884 | 65.496 | 82.229 | 57.985 | 52.187 | 46.989 | 24.794 |
| SG&A
| 109.051 | 127.934 | 121.201 | 153.542 | 151.339 | 214.258 | 166.025 | 184.644 | 168.145 | 212.955 | 212.397 | 231.83 | 215.191 | 232.344 | 166.396 | 176.614 | 131.767 | 139.686 | 119.904 | 96.143 | 84.061 | 45.051 |
| Other Expenses
| 0 | -2.307 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.427 | -0.968 | -0.968 |
| Operating Expenses
| 112.938 | 136.789 | 129.64 | 165.684 | 159.402 | 227.091 | 177.142 | 198.007 | 175.56 | 235.584 | 223.252 | 197.166 | 209.755 | 208.807 | 160.303 | 174.457 | 127.059 | 137.614 | 118.574 | 93.276 | 84.155 | 44.083 |
| Operating Income
| -1.386 | -32.682 | -18.901 | -54.301 | -10.199 | -0.835 | 18.453 | 6.477 | -11.355 | -30.439 | -30.807 | -11.875 | 21.12 | -17.354 | 14.472 | 30.582 | 9.841 | 47.046 | -0.904 | 37.527 | 14.38 | 13.838 |
| Operating Income Ratio
| -0.007 | -0.154 | -0.097 | -0.25 | -0.044 | -0.002 | 0.061 | 0.02 | -0.04 | -0.084 | -0.092 | -0.033 | 0.055 | -0.053 | 0.055 | 0.094 | 0.046 | 0.164 | -0.005 | 0.178 | 0.092 | 0.151 |
| Total Other Income Expenses Net
| -13.23 | -33.116 | -17.613 | -30.182 | -24.5 | -133.743 | -1.067 | 17.352 | 27.743 | -142.963 | -11.941 | 22.714 | -5.428 | 13.898 | -0.685 | -2.301 | 0.545 | -1.671 | -4.337 | -3.32 | -6.257 | -3.255 |
| Income Before Tax
| -14.616 | -65.798 | -36.514 | -84.483 | -34.699 | -134.578 | 17.386 | 23.829 | 16.388 | -173.402 | -42.748 | 10.839 | 15.692 | -3.456 | 13.787 | 28.281 | 10.386 | 45.375 | -5.241 | 34.207 | 8.123 | 10.583 |
| Income Before Tax Ratio
| -0.07 | -0.311 | -0.187 | -0.389 | -0.15 | -0.377 | 0.057 | 0.074 | 0.058 | -0.479 | -0.128 | 0.03 | 0.041 | -0.011 | 0.052 | 0.087 | 0.049 | 0.158 | -0.028 | 0.162 | 0.052 | 0.116 |
| Income Tax Expense
| 3.921 | 2.608 | 1.161 | -4.172 | 5.204 | -0.727 | 5.412 | 3.556 | 4.951 | 8.676 | 2.432 | 3.381 | 2.344 | 3.793 | 4.649 | 4.404 | 2.101 | 9.321 | 2.355 | 6.2 | 1.623 | 1.956 |
| Net Income
| -18.686 | -68.406 | -37.675 | -80.311 | -39.903 | -133.851 | 11.974 | 20.273 | 11.437 | -182.078 | -45.18 | 7.458 | 13.348 | -7.249 | 9.138 | 23.877 | 8.285 | 36.054 | -7.596 | 27.987 | 6.476 | 8.627 |
| Net Income Ratio
| -0.09 | -0.323 | -0.193 | -0.37 | -0.173 | -0.375 | 0.04 | 0.063 | 0.041 | -0.503 | -0.135 | 0.021 | 0.035 | -0.022 | 0.035 | 0.074 | 0.039 | 0.126 | -0.041 | 0.133 | 0.042 | 0.094 |
| EPS
| -0.047 | -0.17 | -0.095 | -0.2 | -0.1 | -0.34 | 0.03 | 0.052 | 0.033 | -0.66 | -0.17 | 0.03 | 0.054 | -0.03 | 0.04 | 0.11 | 0.037 | 0.16 | -0.045 | 0.13 | 13.23 | 17.62 |
| EPS Diluted
| -0.047 | -0.17 | -0.095 | -0.2 | -0.1 | -0.34 | 0.03 | 0.052 | 0.033 | -0.66 | -0.17 | 0.03 | 0.054 | -0.029 | 0.04 | 0.11 | 0.037 | 0.16 | -0.045 | 0.13 | 13.23 | 17.62 |
| EBITDA
| 20.31 | -5.475 | 2.483 | -33.948 | 18.109 | 21.054 | 46.703 | 29.111 | 13.637 | 4.755 | 0.754 | 8.611 | 36.228 | -3.179 | 25.075 | 37.903 | 17.797 | 52.507 | 6.635 | 44.085 | 21.141 | 17.234 |
| EBITDA Ratio
| 0.098 | -0.026 | 0.013 | -0.156 | 0.078 | 0.059 | 0.154 | 0.091 | 0.049 | 0.013 | 0.002 | 0.024 | 0.094 | -0.01 | 0.095 | 0.117 | 0.084 | 0.183 | 0.035 | 0.209 | 0.136 | 0.188 |